Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers
- 30 March 2024
- journal article
- research article
- Published by Elsevier in Cytotherapy
- Vol. 26 (8) , 842-857
Abstract
No abstract availableKeywords
Funding Information
- Skoll Foundation
- Mayo Clinic Arizona
This publication has 148 references indexed in Scilit:
- Functional Validation of the RQR8 Suicide /Marker Gene in CD19 CAR-T Cells and CLL1CAR-T CellsAnnals of Hematology, 2023
- Nano‐optogenetic immunotherapyClinical and Translational Medicine, 2022
- Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)Annals of Oncology, 2022
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- Near‐Infrared‐Light Activatable Nanoparticles for Deep‐Tissue‐Penetrating Wireless OptogeneticsAdvanced Healthcare Materials, 2019
- Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy2018
- Adoptive cellular therapies: the current landscapeVirchows Archiv, 2018
- Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission TomographyMolecular Imaging and Biology, 2016
- iCaspase 9 Suicide Gene System2015